MaaT Pharma, a trailblazer in the development of Microbiome Ecosystem Therapies™, announced positive 18-month survival data for its treatment MaaT013 at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) held in Glasgow. The data, part of an early access program in Europe, highlights the potential of MaaT013 to significantly enhance survival for patients suffering from acute graft-versus-host disease (aGvHD).
The Lyon-based biotech company revealed that the gastrointestinal overall response rate (GI-ORR) for patients treated with MaaT013 reached 52% at Day 28. Notably, the overall survival (OS) rate stood at 42% at 18 months for all patients, and an impressive 58% for those who responded to the treatment.
MaaT013 was particularly effective in third-line treatment scenarios, where it exhibited a 63% GI-ORR at Day 28, and 53% at Day 56, marking the highest overall survival reported in this patient population compared to existing medical literature. These findings underscore MaaT013’s potential as a third-line treatment option, where traditional treatments often fall short.
The ongoing Phase 3 ARES trial, with a cohort of 75 patients, is set to further evaluate the efficacy and safety of MaaT013. This trial targets patients with GI-aGvHD who have not responded to corticosteroids and ruxolitinib, with results anticipated by the end of 2024.
Speaking at the EBMT event, Professor Malard from Sorbonne University emphasized the substantial reduction in disease burden and the improved survival rates associated with MaaT013. He noted the minimal toxicity compared to standard immunosuppressive drugs, highlighting the treatment’s potential to not only extend life but also enhance patient quality of life.
Echoing Professor Malard’s sentiments, Dr. Jaime Sanz Caballer from the University Hospital La Fe in Valencia, Spain, pointed out the urgent need for innovative solutions in treating aGvHD, a condition with historically poor survival outcomes, particularly in third-line treatments.
In addition to its current trials, MaaT Pharma has also initiated a Phase 2b trial for MaaT033, aiming to boost overall survival in allogeneic hematopoietic stem cell transplantation. This international trial will be the largest controlled study of a microbiome-based therapy in oncology to date.
MaaT Pharma continues to leverage its proprietary gutPrint® platform to advance its pipeline of microbiome-based therapies. With MaaT013 already granted Orphan Drug Designation in the U.S. and Europe, the company is poised to meet critical medical needs in oncology and support the broader adoption of microbiome therapies in clinical settings.
